Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.

@article{Parikh2013LongtermCE,
  title={Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.},
  author={Asit Parikh and Irving Fox and Timothy Thierry Leach and Jing Xu and Catherine Scholz and Michael Patella and Brian G Feagan},
  journal={Inflammatory bowel diseases},
  year={2013},
  volume={19 8},
  pages={
          1691-9
        }
}
BACKGROUND Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has shown preliminary efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We report long-term experience with vedolizumab for active UC and CD. METHODS After a placebo-controlled study, 38 patients with UC were randomized to a loading regimen of vedolizumab 2, 6, or 10 mg/kg on days 1, 15, and 43, followed by maintenance dosing every 8 weeks. Thirty-four vedolizumab-naive patients (15 UC; 19 CD) were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
21 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…